Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + dexamethasone salvage therapy after lenalidomide maintenance in relapsed multiple myeloma
ACTRN12615000447550Phase 2Terminated
- Sponsor
- Alfred Health
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Alfred Health. Primary endpoint: Response rate. Started Jun 2015; status: terminated.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12615000447550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000447550.